The content on this site is intended for healthcare professionals only
This module focuses on the effective management of osteonecrosis of the jaw (ONJ) and its challenges. ONJ is a side effect associated with a number of bone-targeting agents approved for use in cancer patients with bone metastases. We look at the importance of communication and collaboration between oncologists, dentists and oral surgeons when it comes to preventing, diagnosing and effectively treating cases of ONJ.
Published September 2017.
This module is designed to support the clinical practise of oncologists, dentists and oral surgeons to aid them in developing an effective management strategy for osteonecrosis of the jaw.
By the end of this module you should be able to:
This module requires the learner to have a good, stable internet connection and can run on Internet Explorer 7 and above, Mozilla Firefox, Google Chrome and Opera on either Windows or MacOS. Flash Add-on is also required to run this module.
If you are viewing this module on an iPad (through a browser), please download the free Articulate Mobile Player beforehand. Other tablet devices may not be compatible - please check for Flash compatibility.
If you are experiencing technical difficulties, please contact education@ecancer.org and we will get back to you as soon as possible.
ecancer and everyone involved in the development of this module has no actual or potential conflict of interest whatsoever which impinges on the making, peer reviewing and dissemination of this e-learning module which was made possible through an unrestricted educational grant from Amgen.
Production of this module was funded by an unrestricted grant from Amgen.
